0
July 14, 1993, Vol 270, No. 2 >
ARTICLE | July 14, 1993

Urology FREE

William J. Catalona, MD
JAMA. 1993;270(2):265-266. doi:10.1001/jama.1993.03510020133048
Text Size: A A A
Published online
Article
References

Recent research results have produced new developments in the areas of prostate cancer and benign prostatic hyperplasia.

The American Cancer Society1 and the American Urological Association2 now recommend annual prostate-specific antigen (PSA) level testing and rectal examinations beginning at the age of 50 years for the early detection of prostate cancer, and beginning at the age of 40 years for high-risk men such as African Americans and those with a strong family history of prostate cancer. An upper age limit has not been set, but routine screening is not desirable in men with a life expectancy of less than 10 years. Annual examinations may be especially important in men who have had a vasectomy, who may have an increased risk of prostate cancer.3 Serial PSA level measurements over an extended period identify men with prostate cancer years before the disease becomes clinically manifest,4 and generally detect

REFERENCES

1 +
Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP.  Defining and updating the American Cancer Society guidelines for cancer-related checkup: prostate and endometrial cancer. CA Cancer J Clin . 1993;;43:42-46.
2 +
American Urological Association.  Early detection of prostate cancer and use of transrectal ultrasound.  In: American Urological Association 1992 Policy Statement Book . Baltimore, Md: American Urological Association; 1992;:420.
3 +
Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC.  A prospective cohort study of vasectomy and prostate cancer in US men. JAMA . 1993;;269:873-877.
4 +
Carter HB, Pearson JO, Metter J, et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA . 1992;;267:2215-2220.
5 +
Catalona WJ, Smith DS, Ratliff TL, et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med . 1991;;324:1156-1161.
6 +
Catalona WJ, Smith DS, Ratliff TL.  Single and serial measurement of serum prostate specific antigen as a screening test for early prostate cancer. J Urol . April 1992;;147( (suppl) ):450.
7 +
Brawn PN, Speights VO, Kuhl D, et al.  Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates. Cancer . 1991;;68:1592-1599.
8 +
Stormont TJ, Farrow GM, Myers RP, et al.  Clinical stage B0 or Tic prostate cancer: non-palpable disease identified by an elevated serum prostate specific antigen concentration. Urology . 1993;;41: 3-8.
9 +
Gerber GS, Thompson IM, Thisted R, Chodak GW.  Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA . 1993;;269:61-64.
10 +
Johansson J-E, Adami H-O, Andersson S-O, Bergström R, Holmberg L, Krusemo UB.  High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA . 1992;;267:2191-2196.
11 +
Simpson KN, Brown RE.  Cost-effectiveness of adding prostate specific antigen (PSA) test to digital rectal examination (DRE) for early detection of prostate cancer. J Urol . 1993;;149:413A.
12 +
Pollard M, Luckert PH, Sporn MB.  Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl) retinamide. Cancer Res . 1991;;51:3610-3611.
13 +
Gormley GJ.  Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors. J Cell Biochem Suppl . 1992;;16H:113-117.
14 +
Presti JC Jr, Fair WR, Andriole GL et al.  Multicenter, randomized double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol . 1992;;148:1201-1204.
15 +
Bosland MC.  Possible enhancement of prostate carcinogenesis by some chemopreventive agents. J Cell Biochem Suppl . 1992;;16H: 135-137.
16 +
Lepor H, Auerbach S, Puras-Baez A, et al.  A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol . 1992;;148:1467-1474.
17 +
Gormley GJ, Stoner E, Bruskewitz RC, et al.  The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med . 1992;;327:1185-1191.
18 +
Barry MJ, Fowler FJ Jr, O'Leary MP, et al.  The American Urological Association symptom index for benign prostatic hyperplasia. J Urol . 1992;;148:1549-1557.
19 +
Geller DM.  Finasteride for benign prostatic hyperplasia (letter to the editor and the authors reply). N Engl J Med . 1993;;328:442-443.
20 +
Lange PH.  Is the prostate pill finally here? New Engl J Med . 1992;;327:1234-1236.
21 +
Pollard M.  The Lobund-Wistar rat model of prostate cancer. J Cell Biochem Suppl . 1992;;16H:84-88.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP.  Defining and updating the American Cancer Society guidelines for cancer-related checkup: prostate and endometrial cancer. CA Cancer J Clin . 1993;;43:42-46.
2 +
American Urological Association.  Early detection of prostate cancer and use of transrectal ultrasound.  In: American Urological Association 1992 Policy Statement Book . Baltimore, Md: American Urological Association; 1992;:420.
3 +
Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC.  A prospective cohort study of vasectomy and prostate cancer in US men. JAMA . 1993;;269:873-877.
4 +
Carter HB, Pearson JO, Metter J, et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA . 1992;;267:2215-2220.
5 +
Catalona WJ, Smith DS, Ratliff TL, et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med . 1991;;324:1156-1161.
6 +
Catalona WJ, Smith DS, Ratliff TL.  Single and serial measurement of serum prostate specific antigen as a screening test for early prostate cancer. J Urol . April 1992;;147( (suppl) ):450.
7 +
Brawn PN, Speights VO, Kuhl D, et al.  Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates. Cancer . 1991;;68:1592-1599.
8 +
Stormont TJ, Farrow GM, Myers RP, et al.  Clinical stage B0 or Tic prostate cancer: non-palpable disease identified by an elevated serum prostate specific antigen concentration. Urology . 1993;;41: 3-8.
9 +
Gerber GS, Thompson IM, Thisted R, Chodak GW.  Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA . 1993;;269:61-64.
10 +
Johansson J-E, Adami H-O, Andersson S-O, Bergström R, Holmberg L, Krusemo UB.  High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA . 1992;;267:2191-2196.
11 +
Simpson KN, Brown RE.  Cost-effectiveness of adding prostate specific antigen (PSA) test to digital rectal examination (DRE) for early detection of prostate cancer. J Urol . 1993;;149:413A.
12 +
Pollard M, Luckert PH, Sporn MB.  Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl) retinamide. Cancer Res . 1991;;51:3610-3611.
13 +
Gormley GJ.  Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors. J Cell Biochem Suppl . 1992;;16H:113-117.
14 +
Presti JC Jr, Fair WR, Andriole GL et al.  Multicenter, randomized double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol . 1992;;148:1201-1204.
15 +
Bosland MC.  Possible enhancement of prostate carcinogenesis by some chemopreventive agents. J Cell Biochem Suppl . 1992;;16H: 135-137.
16 +
Lepor H, Auerbach S, Puras-Baez A, et al.  A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol . 1992;;148:1467-1474.
17 +
Gormley GJ, Stoner E, Bruskewitz RC, et al.  The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med . 1992;;327:1185-1191.
18 +
Barry MJ, Fowler FJ Jr, O'Leary MP, et al.  The American Urological Association symptom index for benign prostatic hyperplasia. J Urol . 1992;;148:1549-1557.
19 +
Geller DM.  Finasteride for benign prostatic hyperplasia (letter to the editor and the authors reply). N Engl J Med . 1993;;328:442-443.
20 +
Lange PH.  Is the prostate pill finally here? New Engl J Med . 1992;;327:1234-1236.
21 +
Pollard M.  The Lobund-Wistar rat model of prostate cancer. J Cell Biochem Suppl . 1992;;16H:84-88.

Letters

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems